Insulet traded at $208.01 this Monday March 30th, decreasing $0.21 or 0.10 percent since the previous trading session. Looking back, over the last four weeks, Insulet lost 15.25 percent. Over the last 12 months, its price fell by 20.79 percent. Looking ahead, we forecast Insulet to be priced at 201.97 by the end of this quarter and at 184.34 in one year, according to Trading Economics global macro models projections and analysts expectations.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.